KRAS and cancer: Thus far, directly targeting oncogenic KRAS only succeeded in one certain form, KRASG12C (12, 13), which comprises only 12% of KRAS mutations in all human cancers, so it is still needed to develop new target molecules for other oncogenic KRAS.